A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain

INVESTIGATORS: Barth Wilsey, M.D. & Thomas Marcotte, Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain

PROJECT TYPE: Clinical Study

STATUS: ACTIVE

ABSTRACT:

This study will involve treating low back pain associated with nerve injury with oral delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.5% Δ9-THC, or placebo. The major objective of the present study is to demonstrate an analgesic response to oral and/or inhaled cannabis in patients with neuropathic low back pain.

The primary outcome will be a pain intensity numerical rating scale bordered by 0=no pain and 10=worst possible pain. As a major goal in the development of cannabinoid-based medications is the separation of pain relief from side-effects, numerous other assessments will also be performed. Neuropsychological testing with the Digit Symbol Modalities Test (attention), the Hopkins Verbal Learning Test (learning and memory) and the Grooved Pegboard Test (psychomotor performance) will be performed. In addition, driving simulation will be completed to assess the effect of study medications on this important component of everyday life. Subjective effects will be evaluated with the Marijuana subscale (M-scale) from the Addiction Research Center Inventory to evaluate cannabis intoxication. In addition, questions that include measures of 'high' or 'liking' will be analyzed.

The degree of pain relief will then be compared with the adverse consequences of cannabis to assess the risk-benefit ratio of dronabinol and 3.5% Δ9-THC.

Interested in participating? Click here to contact us.

Thomas Marcotte, PhD

Presentation before the Canadian House of Commons
(September 2017)


Igor Grant, MD

UC San Diego Department of Psychiatry Grand Rounds: Medicinal Cannabis
(July 2017)




Igor Grant, MD

American Psychological Association Plenary Address: Marijuana as Medicine: Can we see past the smoke?
Denver, CO (August 2016)




Barth Wilsey, MD

Marijuana and Cannabinoids: A Neuroscience Research Summit;
Bethesda, MD (March 2016)



THE PSYCHIATRIC AND NEUROCOGNITIVE EFFECTS OF CANNABIS
(PDF)

Igor Grant, MD, FRCP(C) American Association for the Advancement of Science Annual Meeting

McGill University Health Centre - Research Institute
(February 2015)



Copyright © 2017 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |